Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus fumaric acid esters and methotrexate in systemic-treatment-naive moderate-to-severe plaque psoriasis
2015-002649-69Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixekizumab, dimethyl fumarate + ethyl hydrogen fumarate and methotrexate in plaque psoriasis and psoriasis (4 arms), sponsored by Eli Lilly and Company. Started Jul 2015; status: completed.
02
Drugs
ixekizumabdimethyl fumarate + ethyl hydrogen fumaratemethotrexate
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2015-002649-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002649-69.